628 related articles for article (PubMed ID: 25692384)
1. Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
Wataya-Kaneda M; Tanaka M; Yang L; Yang F; Tsuruta D; Nakamura A; Matsumoto S; Hamasaki T; Tanemura A; Katayama I
JAMA Dermatol; 2015 Jul; 151(7):722-30. PubMed ID: 25692384
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I
JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of autophagy in melanocytes contributes to hypopigmented macules in tuberous sclerosis complex.
Yang F; Yang L; Wataya-Kaneda M; Hasegawa J; Yoshimori T; Tanemura A; Tsuruta D; Katayama I
J Dermatol Sci; 2018 Feb; 89(2):155-164. PubMed ID: 29146131
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Rapamycin in Tuberous Sclerosis-Associated Hypopigmented Macules: Back to the Future.
Arbiser JL
JAMA Dermatol; 2015 Jul; 151(7):703-4. PubMed ID: 25692853
[No Abstract] [Full Text] [Related]
5. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H;
JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048
[TBL] [Abstract][Full Text] [Related]
6. First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex.
Tanaka M; Wataya-Kaneda M; Nakamura A; Matsumoto S; Katayama I
Br J Dermatol; 2013 Dec; 169(6):1314-8. PubMed ID: 23909960
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
Wataya-Kaneda M; Ohno Y; Fujita Y; Yokozeki H; Niizeki H; Ogai M; Fukai K; Nagai H; Yoshida Y; Hamada I; Hio T; Shimizu K; Murota H
JAMA Dermatol; 2018 Jul; 154(7):781-788. PubMed ID: 29800026
[TBL] [Abstract][Full Text] [Related]
8. Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.
Knöpfel N; Martín-Santiago A; Bauza A; Hervás JA
Actas Dermosifiliogr; 2014 Oct; 105(8):802-3. PubMed ID: 24355193
[No Abstract] [Full Text] [Related]
9. Tuberous Sclerosis Complex in 29 Children: Clinical and Genetic Analysis and Facial Angiofibroma Responses to Topical Sirolimus.
Wang S; Liu Y; Wei J; Zhang J; Wang Z; Xu Z
Pediatr Dermatol; 2017 Sep; 34(5):572-577. PubMed ID: 28771801
[TBL] [Abstract][Full Text] [Related]
10. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity.
Wataya-Kaneda M; Tanaka M; Nakamura A; Matsumoto S; Katayama I
Br J Dermatol; 2011 Oct; 165(4):912-6. PubMed ID: 21692771
[TBL] [Abstract][Full Text] [Related]
11. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex.
Balestri R; Neri I; Patrizi A; Angileri L; Ricci L; Magnano M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):14-20. PubMed ID: 25174683
[TBL] [Abstract][Full Text] [Related]
12. Use of mTOR inhibitors (rapalogs) for the treatment of skin changes in tuberous sclerosis complex.
Farges D; Sigg N; Ville D; Martin L
Arch Pediatr; 2022 Dec; 29(5S):5S20-5S24. PubMed ID: 36585067
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of topical rapamycin-calcitriol for facial angiofibromas in patients with tuberous sclerosis complex: a prospective, double-blind, randomized clinical trial.
Chen PL; Hong JB; Shen LJ; Chen YT; Wang SJ; Liao YH
Br J Dermatol; 2020 Oct; 183(4):655-663. PubMed ID: 32064596
[TBL] [Abstract][Full Text] [Related]
14. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.
Hofbauer GF; Marcollo-Pini A; Corsenca A; Kistler AD; French LE; Wüthrich RP; Serra AL
Br J Dermatol; 2008 Aug; 159(2):473-5. PubMed ID: 18547304
[TBL] [Abstract][Full Text] [Related]
15. A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex.
Wataya-Kaneda M; Tanaka M; Nakamura A; Matsumoto S; Katayama I
Arch Dermatol; 2012 Jan; 148(1):138-9. PubMed ID: 22250258
[No Abstract] [Full Text] [Related]
16. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma.
Salido R; Garnacho-Saucedo G; Cuevas-Asencio I; Ruano J; Galán-Gutierrez M; Vélez A; Moreno-Giménez JC
J Eur Acad Dermatol Venereol; 2012 Oct; 26(10):1315-8. PubMed ID: 21834948
[TBL] [Abstract][Full Text] [Related]
17. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.
Cao J; Tyburczy ME; Moss J; Darling TN; Widlund HR; Kwiatkowski DJ
J Clin Invest; 2017 Jan; 127(1):349-364. PubMed ID: 27918305
[TBL] [Abstract][Full Text] [Related]
18. Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature.
Jóźwiak S; Sadowski K; Kotulska K; Schwartz RA
Pediatr Neurol; 2016 Aug; 61():21-7. PubMed ID: 27222056
[TBL] [Abstract][Full Text] [Related]
19. A different approach for identifying hypomelanotic macules in tuberous sclerosis complex.
Gualandri L; Boccardi D; Menni S
G Ital Dermatol Venereol; 2015 Oct; 150(5):501-3. PubMed ID: 26333551
[TBL] [Abstract][Full Text] [Related]
20. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients.
Foster RS; Bint LJ; Halbert AR
Australas J Dermatol; 2012 Feb; 53(1):52-6. PubMed ID: 22309333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
